Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Local deprivation status and seasonal influenza vaccination coverage in adults ≥ 65 years residing in the Foggia municipality, Italy, 2009-2016.

Fortunato F, Iannelli G, Cozza A, Del Prete M, Pollidoro FV, Cocciardi S, DI Trani M, Martinelli D, Prato R.

J Prev Med Hyg. 2019 Feb 28;59(4 Suppl 2):E51-E64. doi: 10.15167/2421-4248/jpmh2018.59.4s2.1167. eCollection 2018 Dec.

2.

Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial.

Del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, Beauregard JM.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):728-742. doi: 10.1007/s00259-018-4209-7. Epub 2018 Nov 30.

PMID:
30506283
3.

Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT.

Del Prete M, Arsenault F, Saighi N, Zhao W, Buteau FA, Celler A, Beauregard JM.

EJNMMI Phys. 2018 Oct 15;5(1):25. doi: 10.1186/s40658-018-0224-9.

4.

Optimal management of resected gastric cancer.

Giampieri R, Del Prete M, Cantini L, Baleani MG, Bittoni A, Maccaroni E, Berardi R.

Cancer Manag Res. 2018 Jun 21;10:1605-1618. doi: 10.2147/CMAR.S151552. eCollection 2018. Review.

5.

The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study.

Faggiano A, Modica R, Severino R, Camera L, Fonti R, Del Prete M, Chiofalo MG, Aria M, Ferolla P, Vitale G, Pezzullo L, Colao A.

Endocrine. 2018 Oct;62(1):46-56. doi: 10.1007/s12020-018-1583-7. Epub 2018 Mar 23.

PMID:
29572709
6.

Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma.

Schneider JR, Shatzkes DR, Scharf SC, Tham TM, Kulason KO, Buteau FA, Del Prete M, Chakraborty S, Anderson TA, Asiry S, Beauregard JM, Langer DJ, Costantino PD, Boockvar JA.

Oper Neurosurg (Hagerstown). 2018 Dec 1;15(6):100-109. doi: 10.1093/ons/opy028.

PMID:
29554305
7.

A Long-Distance RF-Powered Sensor Node with Adaptive Power Management for IoT Applications.

Pizzotti M, Perilli L, Del Prete M, Fabbri D, Canegallo R, Dini M, Masotti D, Costanzo A, Franchi Scarselli E, Romani A.

Sensors (Basel). 2017 Jul 28;17(8). pii: E1732. doi: 10.3390/s17081732.

8.

A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay.

Bianchi F, Maccaroni E, Belvederesi L, Brugiati C, Giampieri R, Bini F, Bracci R, Pagliaretta S, Del Prete M, Piva F, Mandolesi A, Scarpelli M, Berardi R.

Fam Cancer. 2018 Apr;17(2):215-224. doi: 10.1007/s10689-017-0030-x.

PMID:
28785832
9.

Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors.

Del Prete M, Di Sarno A, Modica R, Lassandro F, Giorgio A, Bianco A, Muto M, Gasperi M, Del Prete F, Colao A, Montesarchio V, Faggiano A; ENETS Centre of Excellence Multidisciplinary Group for Neuroendocrine Tumors in Naples (Italy).

J Endocrinol Invest. 2017 Dec;40(12):1373-1380. doi: 10.1007/s40618-017-0723-x. Epub 2017 Jun 30.

PMID:
28667452
10.

Size does matter: Comparison of activity between anti-EGFR and anti-VEGF based-treatments in RAS wild type colorectal cancer patients, stratified by sizes of metastatic involvement.

Del Prete M, Giampieri R, Cantini L, Maccaroni E, Bittoni A, Bruschi A, Silva Rosa R, Bisonni R, Giustini L, Caramanti M, Di Pietro Paolo M, Berardi R.

Ann Oncol. 2017 Jun;28 Suppl 3:iii115-iii116. doi: 10.1093/annonc/mdx261.323. No abstract available.

11.

Primary tumor site (pTS) as a key factor in influencing differential outcome in resected colorectal cancer patients treated with adjuvant XELOX/FOLFOX6.

Giampieri R, Lanese A, Del Prete M, Cantini L, Maccaroni E, Bittoni A, Delprete S, Caramanti M, Pellei C, Meletani T, Baleani Maria G, Di Pietro Paolo M, Berardi R.

Ann Oncol. 2017 Jun;28 Suppl 3:iii108-iii109. doi: 10.1093/annonc/mdx261.307. No abstract available.

12.

Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study.

Del Prete M, Buteau FA, Beauregard JM.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1490-1500. doi: 10.1007/s00259-017-3688-2. Epub 2017 Mar 31.

PMID:
28361189
13.

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.

Bianconi M, Faloppi L, Loretelli C, Zizzi A, Giampieri R, Bittoni A, Andrikou K, Del Prete M, Burattini L, Montironi R, Scartozzi M, Cascinu S.

Oncotarget. 2016 Jun 21;7(25):37599-37607. doi: 10.18632/oncotarget.9229.

14.

The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy.

Giampieri R, Restivo A, Pusceddu V, Del Prete M, Maccaroni E, Bittoni A, Faloppi L, Andrikou K, Bianconi M, Cabras F, Berardi R, Zorcolo L, Scintu F, Cascinu S, Scartozzi M.

Clin Colorectal Cancer. 2017 Mar;16(1):38-43. doi: 10.1016/j.clcc.2016.07.011. Epub 2016 Aug 4.

PMID:
27576095
15.

Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New.

Faloppi L, Bianconi M, Memeo R, Casadei Gardini A, Giampieri R, Bittoni A, Andrikou K, Del Prete M, Cascinu S, Scartozzi M.

Biomed Res Int. 2016;2016:7196280. doi: 10.1155/2016/7196280. Epub 2016 May 29. Review.

16.

Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients.

Giampieri R, Salvatore L, Del Prete M, Prochilo T, D'Anzeo M, Loretelli C, Loupakis F, Aprile G, Maccaroni E, Andrikou K, Bianconi M, Bittoni A, Faloppi L, Demurtas L, Montironi R, Scarpelli M, Falcone A, Zaniboni A, Scartozzi M, Cascinu S.

Sci Rep. 2016 Apr 27;6:25195. doi: 10.1038/srep25195.

17.

The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy.

Faloppi L, Del Prete M, Casadei Gardini A, Santini D, Silvestris N, Bianconi M, Giampieri R, Valgiusti M, Brunetti O, Bittoni A, Andrikou K, Lai E, Dessì A, Cascinu S, Scartozzi M.

Sci Rep. 2016 Apr 11;6:24136. doi: 10.1038/srep24136.

18.

Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.

Giampieri R, Maccaroni E, Mandolesi A, Del Prete M, Andrikou K, Faloppi L, Bittoni A, Bianconi M, Scarpelli M, Bracci R, Scartozzi M, Cascinu S.

Gastric Cancer. 2017 Jan;20(1):156-163. doi: 10.1007/s10120-016-0594-4. Epub 2016 Jan 21.

PMID:
26796888
19.

Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis.

Bittoni A, Del Prete M, Scartozzi M, Pistelli M, Giampieri R, Faloppi L, Bianconi M, Cascinu S.

Springerplus. 2015 Dec 1;4:743. doi: 10.1186/s40064-015-1545-y. eCollection 2015.

20.

Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?

Maccaroni E, Bracci R, Giampieri R, Bianchi F, Belvederesi L, Brugiati C, Pagliaretta S, Del Prete M, Scartozzi M, Cascinu S.

Oncotarget. 2015 Nov 17;6(36):38737-48. doi: 10.18632/oncotarget.5395.

21.

Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management.

Del Prete M, Giampieri R, Loupakis F, Prochilo T, Salvatore L, Faloppi L, Bianconi M, Bittoni A, Aprile G, Zaniboni A, Falcone A, Scartozzi M, Cascinu S.

Oncotarget. 2015 Oct 20;6(32):33982-92. doi: 10.18632/oncotarget.5053.

22.

Panitumumab for the treatment of metastatic colorectal cancer: a review.

Del Prete M, Giampieri R, Faloppi L, Bianconi M, Bittoni A, Andrikou K, Cascinu S.

Immunotherapy. 2015;7(7):721-38. doi: 10.2217/imt.15.46. Epub 2015 Aug 7. Review.

PMID:
26250414
23.

Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer.

Giampieri R, Scartozzi M, Del Prete M, Faloppi L, Bianconi M, Ridolfi F, Cascinu S.

Medicine (Baltimore). 2015 Jun;94(24):e719. doi: 10.1097/MD.0000000000000719.

24.

Predictive factors for sunitinib treatment response in advanced renal cell carcinoma: are we really making steps forward?

Bianconi M, Faloppi L, Del Prete M, Giampieri R, Bittoni A, Lopez-Beltran A, Scarpelli M, Cheng L, Scartozzi M, Cascinu S, Montironi R.

Anal Quant Cytopathol Histpathol. 2015 Feb;37(1):3-13. Review.

PMID:
26072629
25.

Low glycaemic diet and metformin therapy: a new approach in male subjects with acne resistant to common treatments.

Fabbrocini G, Izzo R, Faggiano A, Del Prete M, Donnarumma M, Marasca C, Marciello F, Savastano R, Monfrecola G, Colao A.

Clin Exp Dermatol. 2016 Jan;41(1):38-42. doi: 10.1111/ced.12673. Epub 2015 Jun 6.

PMID:
26053680
26.

[Treatment of pancreatic cancer. Actuality and perspective].

Bittoni A, Andrikou K, Lanese A, Santoni M, Pellei C, Faloppi L, Del Prete M, Giampieri R, Cascinu S.

Recenti Prog Med. 2015 May;106(5):208-16. doi: 10.1701/1868.20404. Italian.

PMID:
25994537
27.

Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab.

Giampieri R, Mandolesi A, Abouelkhair KM, Loretelli C, Del Prete M, Faloppi L, Maristella B, Ibrahim EM, Scarpelli M, Cascinu S, Scartozzi M.

J Transl Med. 2015 May 7;13:140. doi: 10.1186/s12967-015-0501-5.

28.

Prognostic role of the CDNK1B V109G polymorphism in multiple endocrine neoplasia type 1.

Circelli L, Ramundo V, Marotta V, Sciammarella C, Marciello F, Del Prete M, Sabatino L, Pasquali D, Izzo F, Scala S, Colao A, Faggiano A, Colantuoni V; Multidisciplinary Group for NeuroEndocrine Tumours of Naples.

J Cell Mol Med. 2015 Jul;19(7):1735-41. doi: 10.1111/jcmm.12552. Epub 2015 Mar 30.

29.

Selected news from the 2014 Genitourinary Cancers Symposium: translating novel strategies into clinical practice.

Bianconi M, Santoni M, Massari F, Faloppi L, Del Prete M, Giampieri R, Ciccarese C, Modena A, Tortora G, Scartozzi M, Cascinu S.

Future Oncol. 2014 Nov;10(14):2103-6. doi: 10.2217/fon.14.185.

30.

Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis.

Silvestris N, Scartozzi M, Graziano G, Santini D, Lorusso V, Maiello E, Barni S, Cinieri S, Loupakis F, Pisconti S, Brunetti AE, Palasciano G, Palmieri VO, Del Prete M, Dell'Aquila E, Latiano TP, Petrelli F, Lutrino S, Rossini D, Giampieri R, Lotesoriere C, Cascinu S.

Expert Opin Biol Ther. 2015 Feb;15(2):155-62. doi: 10.1517/14712598.2015.986452. Epub 2014 Nov 19.

PMID:
25411089
31.

Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients.

Giampieri R, Aprile G, Del Prete M, Faloppi L, Bianconi M, Bonotto M, Fasola G, Cascinu S, Scartozzi M.

Curr Drug Targets. 2014;15(13):1225-30. Review.

PMID:
25382208
32.

Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib.

Marotta V, Di Somma C, Rubino M, Sciammarella C, Modica R, Camera L, Del Prete M, Marciello F, Ramundo V, Circelli L, Buonomano P, Colao A, Faggiano A.

Endocrine. 2015 Aug;49(3):854-8. doi: 10.1007/s12020-014-0448-y. Epub 2014 Oct 11. No abstract available.

PMID:
25305056
33.

Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication.

Marotta V, Di Somma C, Rubino M, Sciammarella C, Del Prete M, Marciello F, Ramundo V, Circelli L, Buonomano P, Modica R, Vitale M, Colao A, Faggiano A.

Endocrine. 2015 May;49(1):274-8. doi: 10.1007/s12020-014-0381-0. Epub 2014 Aug 15. No abstract available.

PMID:
25123977
34.

The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer.

Giampieri R, Scartozzi M, Del Prete M, Fulli A, Faloppi L, Bianconi M, Maccaroni E, Cascinu S.

Cancer Treat Rev. 2014 Sep;40(8):934-41. doi: 10.1016/j.ctrv.2014.06.004. Epub 2014 Jun 20.

PMID:
24997679
35.

Hepatic arterial embolization in patients with neuroendocrine tumors.

Del Prete M, Fiore F, Modica R, Marotta V, Marciello F, Ramundo V, Di Sarno A, Carratù A, di Roseto Cde L, Tafuto S, Tatangelo F, Baldelli R, Colao A, Faggiano A; Multidisciplinary Group for NeuroEndocrine Tumors of Naples.

J Exp Clin Cancer Res. 2014 May 19;33:43. doi: 10.1186/1756-9966-33-43. Review.

36.

The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment.

D'Anzeo M, Faloppi L, Scartozzi M, Giampieri R, Bianconi M, Del Prete M, Silvestris N, Cascinu S.

Molecules. 2014 May 19;19(5):6393-406. doi: 10.3390/molecules19056393. Review.

37.

The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management.

Faloppi L, Scartozzi M, Bianconi M, Svegliati Baroni G, Toniutto P, Giampieri R, Del Prete M, De Minicis S, Bitetto D, Loretelli C, D'Anzeo M, Benedetti A, Cascinu S.

BMC Cancer. 2014 Feb 20;14:110. doi: 10.1186/1471-2407-14-110.

38.

Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours.

Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, De Luca L, Circelli L, Colantuoni V, Di Sarno A, Carratù AC, de Luca di Roseto C, Colao A, Faggiano A; Multidisciplinary Group for Neuroendocrine Tumors of Naples.

Clin Endocrinol (Oxf). 2014 Jun;80(6):850-5. doi: 10.1111/cen.12411. Epub 2014 Feb 19.

PMID:
24443791
39.

Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas.

Marciello F, Di Somma C, Del Prete M, Marotta V, Ramundo V, Carratù A, de Luca di Roseto C, Camera L, Colao A, Faggiano A.

Endocrine. 2014 Aug;46(3):678-81. doi: 10.1007/s12020-013-0145-2. Epub 2014 Jan 3.

PMID:
24385268
40.

Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors.

Fiore F, Del Prete M, Franco R, Marotta V, Ramundo V, Marciello F, Di Sarno A, Carratù AC, de Luca di Roseto C, Colao A, Faggiano A.

Endocrine. 2014 Sep;47(1):177-82. doi: 10.1007/s12020-013-0130-9. Epub 2014 Jan 3.

PMID:
24385266
41.

Quality of life measurement and outcome in aphasia.

Spaccavento S, Craca A, Del Prete M, Falcone R, Colucci A, Di Palma A, Loverre A.

Neuropsychiatr Dis Treat. 2014;10:27-37. doi: 10.2147/NDT.S52357. Epub 2013 Dec 17.

42.

A case of atypical progressive supranuclear palsy.

Spaccavento S, Del Prete M, Craca A, Loverre A.

Clin Interv Aging. 2014;9:31-9. doi: 10.2147/CIA.S51640. Epub 2013 Dec 16.

43.

Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.

Del Prete M, Marotta V, Ramundo V, Marciello F, Di Sarno A, Esposito R, Carratù AC, De Luca Di Roseto C, Di Somma C, Colao A, Faggiano A.

Minerva Endocrinol. 2013 Dec;38(4):389-94.

PMID:
24285106
44.

Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey.

Scartozzi M, Giampieri R, Del Prete M, Faloppi L, Bianconi M, Vincenzi B, Tonini G, Santini D, Cascinu S.

Expert Opin Pharmacother. 2014 Jan;15(1):143-50. doi: 10.1517/14656566.2014.860964. Epub 2013 Nov 28.

PMID:
24283747
45.

Clinical evidence for three distinct gastric cancer subtypes: time for a new approach.

Bittoni A, Scartozzi M, Giampieri R, Faloppi L, Bianconi M, Mandolesi A, Del Prete M, Pistelli M, Cecchini L, Bearzi I, Cascinu S.

PLoS One. 2013 Nov 12;8(11):e78544. doi: 10.1371/journal.pone.0078544. eCollection 2013.

46.

Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients.

Scartozzi M, Giampieri R, Loretelli C, Bittoni A, Mandolesi A, Faloppi L, Bianconi M, Del Prete M, Andrikou K, Bearzi I, Cascinu S.

Pharmacogenomics. 2013 Dec;14(16):1991-8. doi: 10.2217/pgs.13.185. Epub 2013 Oct 3.

47.

Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients.

Giampieri R, Scartozzi M, Loretelli C, Piva F, Mandolesi A, Lezoche G, Del Prete M, Bittoni A, Faloppi L, Bianconi M, Cecchini L, Guerrieri M, Bearzi I, Cascinu S.

PLoS One. 2013 Sep 4;8(9):e72843. doi: 10.1371/journal.pone.0072843. eCollection 2013.

48.

Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation.

Giampieri R, Scartozzi M, Del Prete M, Maccaroni E, Bittoni A, Faloppi L, Bianconi M, Cecchini L, Cascinu S.

Crit Rev Oncol Hematol. 2013 Nov;88(2):272-83. doi: 10.1016/j.critrevonc.2013.05.008. Epub 2013 Jun 24. Review.

PMID:
23806981
49.

Targeted therapy with kinase inhibitors in aggressive endocrine tumors.

Marotta V, Franzese MD, Del Prete M, Chiofalo MG, Ramundo V, Esposito R, Marciello F, Pezzullo L, Carratù A, Vitale M, Colao A, Faggiano A.

Expert Opin Pharmacother. 2013 Jun;14(9):1187-203. doi: 10.1517/14656566.2013.796931. Review.

PMID:
23675883
50.

Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab.

Scartozzi M, Giampieri R, Loretelli C, Mandolesi A, del Prete M, Biagetti S, Alfonsi S, Faloppi L, Bianconi M, Bittoni A, Bearzi I, Cascinu S.

Future Oncol. 2013 Aug;9(8):1207-14. doi: 10.2217/fon.13.72. Epub 2013 Apr 26.

PMID:
23617461

Supplemental Content

Loading ...
Support Center